Neuromodulator / Allergan Aesthetics · AbbVie
BOTOX Cosmetic
OnabotulinumtoxinA, with a close look at regional labels and the science of facial feedback.
Product Atlas · September 2026
The exact product comes first
Scope of this monograph#
Clinical summary: BOTOX Cosmetic, US. VISTABEL and Australian BOTOX are separate regional records.
Clinical statements below summarize the attached documents. They are not a complete prescribing label. Match the exact local product and current instructions to the clinical decision.
Composition & formulation#
OnabotulinumtoxinA in a dried formulation for reconstitution. The US label lists 50- and 100-unit single-dose vials.[2]
How it works#
Inhibits acetylcholine release at cholinergic nerve terminals, temporarily reducing activity in the treated muscles.[2]
Indications & treatment areas#
The US label covers moderate-to-severe glabellar, lateral canthal and forehead lines, and platysma bands in adults. These indications cannot be transferred to VISTABEL.[2][3]
Application considerations#
Intramuscular use requires anatomical assessment and product-specific preparation. Potency units cannot be converted to those of another toxin.[2]
Contraindications & precautions#
Contraindicated with relevant hypersensitivity or infection at the injection site. Neuromuscular disease, dysphagia and interacting medicines require particular assessment.[2]
Adverse effects & safety#
Ptosis, headache and local reactions occur. Distant toxin spread can impair swallowing or breathing and requires urgent medical attention.[2]
Duration & follow-up#
Effects are temporary and depend on the treated indication and endpoint. Consult the indication-specific clinical-study section rather than a single family-wide duration.[2]
Distinctions that matter#
Facial-feedback research studies neural activity, not an approved psychiatric treatment indication. A mechanistic finding must not become a therapeutic promise.[5][2]
Four markets. Separate evidence.#
Documents below identify what has been attached in this research edition. “Source needed” means unverified here; it is not a statement that a product is unapproved.
German product information for VISTABEL; no equivalence of indications is inferred.[3]
UK SmPC updated May 2026 includes facial-line uses and platysma prominence. This is a separate regional presentation from US BOTOX Cosmetic.[1]
US label includes platysma bands following its October 2024 update.[2]
ARTG 67311 identifies the Australian presentation; the local PI must be used for prescribing.[4]
Studies worth a closer look.#
Can changing a frown change neural processing?
Interesting neuroscience, not evidence to promise improved mental health.
Follow the evidence.#
Retrieved 6 September 2026. A retrieval date does not establish that an older document is the latest approved revision. Studies marked “abstract” have not completed full-text appraisal.
- [1] BOTOX 200 units UK Summary of Product Characteristics ↗AbbVie / emc · label · Document accessed · Document: 15 May 2026 · Checked 2026-09-06
- [2] BOTOX Cosmetic prescribing information ↗Allergan / DailyMed · label · Document accessed · Document: October 2024 · Checked 2026-09-06
- [3] VISTABEL German Fachinformation ↗AbbVie / Fachinfo · label · Document accessed · Document: January 2024 · Checked 2026-09-06
- [4] BOTOX 100 U — ARTG 67311 ↗Therapeutic Goods Administration · regulator · Document accessed · Checked 2026-09-06
- [5] Stark et al. — facial feedback and amygdala activity ↗Scientific Reports, 2023 · PMID 36849797 · study · Abstract accessed · Checked 2026-09-06
Cite this monograph#
Aesthetic Pass. BOTOX Cosmetic. Product Atlas research edition 2026.09.06.1. https://aestheticpass.com/products/monographs/botox-cosmetic/